WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319554
Description: Nelonicline, aslo known as ABT-126, is an Alpha7 nicotinic acetylcholine receptor agonist and Nicotinic acetylcholine receptor agonist. Nelonicline is potentially useful for the treatment of Alzheimer's diseases. ABT-126 may be useful to reduce dyskinesias in both early- and later-stage Parkinson's disease. Accumulating evidence suggests that the α7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a key role in inflammatory processes, thought to be involved in the pathophysiology of neuropsychiatric diseases, such as schizophrenia and Alzheimer's disease.
MedKoo Cat#: 319554
Chemical Formula: C17H19N3OS
Exact Mass: 313.1249
Molecular Weight: 313.42
Elemental Analysis: C, 65.15; H, 6.11; N, 13.41; O, 5.10; S, 10.23
Nelonicline is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: ABT-126; ABT126; ABT 126; Nelonicline
IUPAC/Chemical Name: 2-(((3R,4r,5S,7s)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole
InChi Key: QZDCYUCETTWCMO-OFTMQHFLSA-N
InChi Code: InChI=1S/C17H19N3OS/c1-2-4-12(5-3-1)16-18-19-17(22-16)21-15-13-6-11-7-14(15)10-20(8-11)9-13/h1-5,11,13-15H,6-10H2/t11-,13-,14+,15+
SMILES Code: C1(C(S2)=NN=C2O[C@@H]3[C@H]4C[C@H]5C[C@@H]3CN(C4)C5)=CC=CC=C1
The following data is based on the product molecular weight 313.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M. α7
nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe
nigrostriatal damage. Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26453. [Epub
ahead of print] Review. PubMed PMID: 26573698.
2: Hashimoto K. Targeting of α7 Nicotinic Acetylcholine Receptors in the
Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a
Translational Biomarker. Curr Pharm Des. 2015;21(26):3797-806. PubMed PMID: